Mardil Medical Inc.
Ventricular reshaping to treat functional mitral regurgitation
This article was originally published in Start Up
Mardil Medical Inc.’s VenTouch System for treating functional mitral valve regurgitation is intended to reshape and correct the geometry of the dilated heart, reduce or eliminate mitral valve regurgitation, and reduce heart wall stressors, all leading to a beneficial reverse remodeling effect.
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.